The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Endothelin in human congestive heart failure.
Abstract
BACKGROUND: Although recent investigations report the elevation of plasma endothelin (ET) in congestive heart failure (CHF), it remains unclear if this elevation is that of the biologically active peptide ET-1 or of its precursor big-ET. Furthermore, it is unclear if such elevation is associated with increased myocardial ET and if the molecular form from cardiac tissue is altered ET. Last, it remains to be established whether circulating ET is increased at the earliest stage of CHF in patients with asymptomatic left ventricular dysfunction and correlates with the magnitude of ventricular dysfunction. METHODS AND RESULTS: The present study was designed to investigate concentrations and molecular forms of ET in plasma and cardiac tissue in healthy subjects and CHF patients with New York Heart Association (NYHA) class I through IV using cardiac radionuclide angiogram, cardiac myocardial biopsy, radioimmunoassay, gel permeation chromatography (GPC), and immunohistochemical staining (IHCS). Plasma ET was increased only in patients with moderate (NYHA class III) or severe (NYHA class IV) CHF compared with healthy subjects and individuals with asymptomatic (NYHA class I) or mild (NYHA class II) CHF. The elevation of circulating ET in CHF showed a negative correlation with left ventricular ejection fraction and cardiac index and a positive correlation with functional class and left ventricular end-diastolic volume index. GPC demonstrated that immunoreactive plasma ET was ET-1 in healthy subjects and both mature ET-1 and its precursor big-ET in severe CHF patients, with big-ET the predominant molecular form. Cardiac tissue concentrations and IHCS revealed ET presence in healthy atrial and ventricular tissue, which were not different in severe CHF. GPC revealed that the molecular form of cardiac ET was ET-1 in both healthy and CHF hearts. CONCLUSIONS: The present study establishes for the first time that the elevation of plasma ET in severe human CHF represents principally elevation of big-ET. Second, ET is present in healthy and failing myocardia, and its activity by both immunohistochemistry and radioimmunoassay is not changed in CHF. Furthermore, the elevated plasma ET is characteristic of severe CHF and not asymptomatic or mild CHF. In addition, the degree of plasma elevation of ET correlates with the magnitude of alterations in cardiac hemodynamics and functional class. The present study confirms and extends previous investigations of ET in human CHF and establishes the evolution of circulating and local cardiac ET in the spectrum of human CHF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,729
Bone, R. C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-6-457 · Cited by 1,368
Packer, M. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90167-l · Cited by 1,056
Circulating and Tissue Endothelin Immunoreactivity in Advanced Atherosclerosis
Lerman, A., Edwards, B. S., Hallett, J. W., Heublein, D. M., Sandberg, S. M., & Burnett, J. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110033251404 · Cited by 953
Self-citationSimonson, M. S., Wann, S., Mené, P., Dubyak, G. R., Kester, M., Nakazato, Y., Sedor, J. R., & Dunn, M. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113935 · Cited by 555
Endothelial function in chronic congestive heart failure
Drexler, H., Hayoz, D., Münzel, T., Hornig, B., Just, H., Brunner, H. R., & Zelis, R. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90710-g · Cited by 550
Integrated cardiac, renal, and endocrine actions of endothelin.
Miller, W. L., Redfield, M. M., & Burnett, J. C. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113876 · Cited by 473
Self-citationEgashira, K., Inou, T., Hirooka, Y., Yamada, A., Maruoka, Y., Kai, H., Sugimachi, M., Suzuki, S., & Takeshita, A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116183 · Cited by 357
Increased plasma endothelin-1 in the early hours of acute myocardial infarction
Stewart, D. J., Kubac, G., Costello, K. B., & Cernacek, P. (1991) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)80214-1 · Cited by 295
PLASMA ENDOTHELIN LEVELS IN PATIENTS WITH URAEMIA
Koyama, H., Nishzawa, Y., Morii, H., Tabata, T., Inoue, T., & Yamaji, T. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92631-7 · Cited by 286
Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay
Sugiura, M., Inagami, T., & Kon, V. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91372-7 · Cited by 260
Toyo-oka, T., Aizawa, T., Suzuki, N., Hirata, Y., Miyauchi, T., Shin, W. S., Yanagisawa, M., Masaki, T., & Sugimoto, T. (1991) · Circulation · doi:10.1161/01.cir.83.2.476 · Cited by 246
Endothelin is a positive inotropic agent in human and rat heart in, vitro
Moravec, C. S., Reynolds, E. E., Stewart, R. W., & Bond, M. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92397-8 · Cited by 232
Rubanyi, G. M., & Botelho, L. H. P. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.12.1916094 · Cited by 219
Increased Plasma Concentrations of Endothelin in Congestive Heart Failure in Humans
RODEHEFFER, R. J., LERMAN, A., HEUBLEIN, D. M., & BURNETT, J. C. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60795-2 · Cited by 192
Self-citationEndothelin in myocardial infarction
WATANABE, T., SUZUKI, N., SHIMAMOTO, N., FUJINO, M., & IMADA, A. (1990) · Nature · doi:10.1038/344114a0 · Cited by 177
Lerman, A., Kubo, S. H., Tschumperlin, L. K., & Burnett, J. C. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90183-n · Cited by 158
Self-citationCozza, E. N., Gómez-Sánchez, C. E., Foecking, M. F., & Chiou, S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114226 · Cited by 157
Progression of aortic stenosis in adults: Newappraisal using doppler echocardiography
Roger, V. L., Tajik, A. J., Bailey, K. R., Oh, J. K., Taylor, C. L., & Seward, J. B. (1990) · American Heart Journal · doi:10.1016/s0002-8703(05)80024-9 · Cited by 114
Endothelium-derived relaxing and contracting factors: Perspectives in nephrology
Lüscher, T. F., Bock, H. A., Yang, Z., & Diederich, D. A. (1991) · Kidney International · doi:10.1038/ki.1991.68 · Cited by 108
Cited by
Molecular Mechanisms of Myocardial Remodeling
SWYNGHEDAUW, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.215 · Cited by 1,460
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
“In these patients, circulating concentrations of precursor BigET-1, or those of the active peptide itself are enhanced and constitute independent predictors of morbidity and mortality (Wei et al. 1994, Masson et al. 2006, Gottlieb et al. 2015).”
BackgroundBozkurt, B., Kribbs, S. B., Clubb, F. J., Michael, L. H., Didenko, V. V., Hornsby, P. J., Seta, Y., Oral, H., Spinale, F. G., & Mann, D. L. (1998) · Circulation · doi:10.1161/01.cir.97.14.1382 · Cited by 821
Levin, E. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508103330607 · Cited by 711
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622
Metadata
- Authors
- Wei, C. M., Lerman, A., Rodeheffer, R. J., McGregor, C. G., Brandt, R. R., Wright, S., Heublein, D. M., Kao, P. C., Edwards, W. D., & Burnett, J. C.
- Venue
- Circulation
- Published
- 1994-04
- Volume
- 89
- Issue
- 4
- Pages
- 1580-1586
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1993972994
- Cited by
- 586
- References
- 20
- FWCI
- 17.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.